Ignite Creation Date:
2025-12-25 @ 2:05 AM
Ignite Modification Date:
2025-12-26 @ 2:25 AM
Study NCT ID:
NCT07224360
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-11-04
First Post:
2025-10-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Sponsor:
CSL Behring
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-11-15
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-06-29
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-06-29
Completion Date Type:
ESTIMATED
First Submit Date:
2025-10-31
First Submit QC Date:
None
Study First Post Date:
2025-11-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-31
Last Update Post Date:
2025-11-04
Last Update Post Date Type:
ESTIMATED